Home - Abcuro

Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease

news

Abcuro Announces $66 Million Series D Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis

August 18, 2026

Proceeds to support a potentially registrational clinical study in less severe inclusion body myositis (IBM) patients expected to begin in Q4 2026 and report top line results in 2H 2028 Ulviprubart showed a trend toward clinically meaningful slowing of disease progression in patients with less severe IBM in the previous Phase 2/3 MUSCLE study Series

August 18, 2026

Abcuro Announces $66 Million Series D Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body MyositisPress Releases

Targeting Highly Cytotoxic T Cells

Highly cytotoxic T cells have been implicated as mediators of tissue damage in many autoimmune diseases

Ulviprubart in Autoimmune Disorders

Ulviprubart, an investigational monoclonal antibody, selectively depletes highly cytotoxic T cells

Inclusion Body Myositis

Inclusion body myositis (IBM) is a debilitating chronic, progressive disorder in which muscle is destroyed by highly cytotoxic T cells